News

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

“We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s Lab-to-Launch initiative,” said Mike Grisham, CEO of Virginia Catalyst. “Collaboration between our research universities and industry drives innovations that contribute to economic development in the Commonwealth.”

We encourage those of you with innovative ideas in life sciences to reach out to colleagues and other professionals to create a high-performing team. World-class research, entrepreneurial management, and capital can achieve great things together. You have several months to get a team together and submit an LOI by January 16. We award non-dilutive grants of $200k to $800k, plus we provide great contacts with other sources of capital and strategic partnerships.

Letters of Intent (LOI) must be received by January 16, 2026, at 5:00 PM Eastern Time. Projects that meet funding criteria will be invited to submit a full application by March 20, 2026. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists, and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to present their proposal in April, and awards will be announced in May 2026. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding, and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH, and philanthropic foundations. This webinar can be viewed, and the slides downloaded, on the home page of Virginia Catalyst at: https://www.virginiacatalyst.org/

Cumulatively, through the first 18 funding rounds, Virginia Catalyst has dedicated a total of over $38 million for 72 collaborative projects. Together, these projects have created over 450 new jobs and have attracted nearly $900 million of investment capital from venture capital, private equity, corporations, and government agencies including DARPA, NIH, and NSF, as well as through acquisitions.

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …